1079 related articles for article (PubMed ID: 15163750)
21. Lytic but not latent infection by Kaposi's sarcoma-associated herpesvirus requires host CSL protein, the mediator of Notch signaling.
Liang Y; Ganem D
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8490-5. PubMed ID: 12832621
[TBL] [Abstract][Full Text] [Related]
22. X box binding protein XBP-1s transactivates the Kaposi's sarcoma-associated herpesvirus (KSHV) ORF50 promoter, linking plasma cell differentiation to KSHV reactivation from latency.
Wilson SJ; Tsao EH; Webb BL; Ye H; Dalton-Griffin L; Tsantoulas C; Gale CV; Du MQ; Whitehouse A; Kellam P
J Virol; 2007 Dec; 81(24):13578-86. PubMed ID: 17928342
[TBL] [Abstract][Full Text] [Related]
23. Kaposi's sarcoma-associated herpesvirus-encoded LANA interacts with host KAP1 to facilitate establishment of viral latency.
Sun R; Liang D; Gao Y; Lan K
J Virol; 2014 Jul; 88(13):7331-44. PubMed ID: 24741090
[TBL] [Abstract][Full Text] [Related]
24. The single RBP-Jkappa site within the LANA promoter is crucial for establishing Kaposi's sarcoma-associated herpesvirus latency during primary infection.
Lu J; Verma SC; Cai Q; Robertson ES
J Virol; 2011 Jul; 85(13):6148-61. PubMed ID: 21507979
[TBL] [Abstract][Full Text] [Related]
25. CCAAT/enhancer-binding protein-alpha is induced during the early stages of Kaposi's sarcoma-associated herpesvirus (KSHV) lytic cycle reactivation and together with the KSHV replication and transcription activator (RTA) cooperatively stimulates the viral RTA, MTA, and PAN promoters.
Wang SE; Wu FY; Yu Y; Hayward GS
J Virol; 2003 Sep; 77(17):9590-612. PubMed ID: 12915572
[TBL] [Abstract][Full Text] [Related]
26. ARID3B: a Novel Regulator of the Kaposi's Sarcoma-Associated Herpesvirus Lytic Cycle.
Wood JJ; Boyne JR; Paulus C; Jackson BR; Nevels MM; Whitehouse A; Hughes DJ
J Virol; 2016 Oct; 90(20):9543-55. PubMed ID: 27512077
[TBL] [Abstract][Full Text] [Related]
27. Promoter switching allows simultaneous transcription of LANA and K14/vGPCR of Kaposi's sarcoma-associated herpesvirus.
Staudt MR; Dittmer DP
Virology; 2006 Jun; 350(1):192-205. PubMed ID: 16616289
[TBL] [Abstract][Full Text] [Related]
28. Kaposi's sarcoma-associated herpesvirus terminal repeat regulates inducible lytic gene promoters.
Izumiya Y; Algalil A; Espera JM; Miura H; Izumiya C; Inagaki T; Kumar A
J Virol; 2024 Feb; 98(2):e0138623. PubMed ID: 38240593
[TBL] [Abstract][Full Text] [Related]
29. NCOA2 promotes lytic reactivation of Kaposi's sarcoma-associated herpesvirus by enhancing the expression of the master switch protein RTA.
Wei X; Bai L; Dong L; Liu H; Xing P; Zhou Z; Wu S; Lan K
PLoS Pathog; 2019 Nov; 15(11):e1008160. PubMed ID: 31751430
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of replication and transcription activator and latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus by morpholino oligomers.
Zhang YJ; Wang KY; Stein DA; Patel D; Watkins R; Moulton HM; Iversen PL; Matson DO
Antiviral Res; 2007 Jan; 73(1):12-23. PubMed ID: 16842866
[TBL] [Abstract][Full Text] [Related]
31. The transcriptional repressor K-RBP modulates RTA-mediated transactivation and lytic replication of Kaposi's sarcoma-associated herpesvirus.
Yang Z; Wood C
J Virol; 2007 Jun; 81(12):6294-306. PubMed ID: 17409159
[TBL] [Abstract][Full Text] [Related]
32. ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection.
Sharma-Walia N; Krishnan HH; Naranatt PP; Zeng L; Smith MS; Chandran B
J Virol; 2005 Aug; 79(16):10308-29. PubMed ID: 16051824
[TBL] [Abstract][Full Text] [Related]
33. Kaposi's sarcoma herpesvirus latency-associated nuclear antigen broadly regulates viral gene expression and is essential for lytic infection.
Li S; Wang M; Van Sciver N; Szymula A; Tumuluri VS; George A; Ramachandran A; Raina K; Costa CN; Zhao B; Kazemian M; Simas JP; Kaye KM
PLoS Pathog; 2024 Jan; 20(1):e1011907. PubMed ID: 38232124
[TBL] [Abstract][Full Text] [Related]
34. Direct interactions of Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50/Rta protein with the cellular protein octamer-1 and DNA are critical for specifying transactivation of a delayed-early promoter and stimulating viral reactivation.
Carroll KD; Khadim F; Spadavecchia S; Palmeri D; Lukac DM
J Virol; 2007 Aug; 81(16):8451-67. PubMed ID: 17537858
[TBL] [Abstract][Full Text] [Related]
35. Genetic disruption of KSHV major latent nuclear antigen LANA enhances viral lytic transcriptional program.
Li Q; Zhou F; Ye F; Gao SJ
Virology; 2008 Sep; 379(2):234-44. PubMed ID: 18684478
[TBL] [Abstract][Full Text] [Related]
36. Promoter- and cell-specific transcriptional transactivation by the Kaposi's sarcoma-associated herpesvirus ORF57/Mta protein.
Palmeri D; Spadavecchia S; Carroll KD; Lukac DM
J Virol; 2007 Dec; 81(24):13299-314. PubMed ID: 17913801
[TBL] [Abstract][Full Text] [Related]
37. Identification and characterization of a new Kaposi's sarcoma-associated herpesvirus replication and transcription activator (RTA)-responsive element involved in RTA-mediated transactivation.
Wen HJ; Minhas V; Wood C
J Gen Virol; 2009 Apr; 90(Pt 4):944-953. PubMed ID: 19223488
[TBL] [Abstract][Full Text] [Related]
38. Site-specific association with host and viral chromatin by Kaposi's sarcoma-associated herpesvirus LANA and its reversal during lytic reactivation.
Mercier A; Arias C; Madrid AS; Holdorf MM; Ganem D
J Virol; 2014 Jun; 88(12):6762-77. PubMed ID: 24696474
[TBL] [Abstract][Full Text] [Related]
39. Kaposi's Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen Inhibits Major Histocompatibility Complex Class II Expression by Disrupting Enhanceosome Assembly through Binding with the Regulatory Factor X Complex.
Thakker S; Purushothaman P; Gupta N; Challa S; Cai Q; Verma SC
J Virol; 2015 May; 89(10):5536-56. PubMed ID: 25740990
[TBL] [Abstract][Full Text] [Related]
40. Kaposi's sarcoma-associated herpesvirus transactivator RTA promotes degradation of the repressors to regulate viral lytic replication.
Yang Z; Yan Z; Wood C
J Virol; 2008 Apr; 82(7):3590-603. PubMed ID: 18216089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
